BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Leerink Swann raised their Q3 2017 earnings per share estimates for BioMarin Pharmaceutical in a report released on Wednesday. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will post earnings of ($0.02) per share for the quarter, up from their prior estimate of ($0.09). Leerink Swann has a “Buy” rating on the stock. Leerink Swann also issued estimates for BioMarin Pharmaceutical’s Q4 2017 earnings at ($0.28) EPS and FY2017 earnings at ($0.59) EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. The company had revenue of $317.50 million during the quarter, compared to the consensus estimate of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.61) EPS.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/07/leerink-swann-comments-on-biomarin-pharmaceutical-inc-s-q3-2017-earnings-nasdaqbmrn.html.

Several other analysts have also commented on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $107.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday. Cowen and Company reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Friday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $119.00 price objective (up previously from $118.00) on shares of BioMarin Pharmaceutical in a report on Thursday. UBS AG reaffirmed a “neutral” rating and issued a $93.00 price objective (up previously from $92.00) on shares of BioMarin Pharmaceutical in a report on Thursday. Finally, Sanford C. Bernstein began coverage on BioMarin Pharmaceutical in a report on Thursday, July 27th. They issued a “market perform” rating and a $89.00 price objective for the company. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have assigned a buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Hold” and an average target price of $110.20.

BioMarin Pharmaceutical (NASDAQ:BMRN) opened at 89.70 on Monday. BioMarin Pharmaceutical has a 1-year low of $78.42 and a 1-year high of $102.49. The stock’s 50 day moving average price is $90.43 and its 200 day moving average price is $90.03. The company’s market cap is $15.72 billion.

In other news, insider Henry J. Fuchs sold 15,000 shares of the company’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $90.00, for a total value of $1,350,000.00. Following the completion of the transaction, the insider now owns 141,422 shares of the company’s stock, valued at $12,727,980. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian Mueller sold 2,671 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $267,100.00. Following the completion of the transaction, the senior vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,555,600. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,740 shares of company stock valued at $5,659,589. Corporate insiders own 2.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its stake in BioMarin Pharmaceutical by 13.6% in the first quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company’s stock worth $100,000 after buying an additional 125 shares in the last quarter. Nikko Asset Management Americas Inc. purchased a new stake in BioMarin Pharmaceutical during the first quarter worth approximately $114,000. Global X Management Co. LLC increased its stake in BioMarin Pharmaceutical by 59.7% in the first quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock worth $145,000 after buying an additional 619 shares in the last quarter. Korea Investment CORP increased its stake in BioMarin Pharmaceutical by 143.5% in the second quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock worth $145,000 after buying an additional 940 shares in the last quarter. Finally, Toronto Dominion Bank increased its stake in BioMarin Pharmaceutical by 27.1% in the first quarter. Toronto Dominion Bank now owns 1,881 shares of the biotechnology company’s stock worth $165,000 after buying an additional 401 shares in the last quarter. 96.82% of the stock is owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.